JPMorgan Chase & Co. Purchases 7,594 Shares of Sotera Health (NASDAQ:SHC)

JPMorgan Chase & Co. lifted its position in Sotera Health (NASDAQ:SHC) by 3.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 255,341 shares of the company’s stock after acquiring an additional 7,594 shares during the period. JPMorgan Chase & Co.’s holdings in Sotera Health were worth $3,493,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in shares of Sotera Health by 19.4% during the third quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock valued at $46,026,000 after purchasing an additional 447,186 shares during the period. Barclays PLC increased its stake in Sotera Health by 169.8% in the 3rd quarter. Barclays PLC now owns 473,597 shares of the company’s stock worth $7,909,000 after buying an additional 298,085 shares during the period. KBC Group NV lifted its holdings in Sotera Health by 4,094.6% during the 4th quarter. KBC Group NV now owns 186,365 shares of the company’s stock valued at $2,549,000 after buying an additional 181,922 shares in the last quarter. SG Americas Securities LLC boosted its position in Sotera Health by 271.6% in the 4th quarter. SG Americas Securities LLC now owns 36,364 shares of the company’s stock valued at $497,000 after buying an additional 26,577 shares during the period. Finally, Envestnet Portfolio Solutions Inc. boosted its position in Sotera Health by 17.3% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 15,839 shares of the company’s stock valued at $217,000 after buying an additional 2,340 shares during the period. 91.03% of the stock is owned by hedge funds and other institutional investors.

Sotera Health Trading Down 1.5 %

NASDAQ SHC opened at $10.32 on Tuesday. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The company’s 50-day simple moving average is $11.76 and its two-hundred day simple moving average is $13.26. Sotera Health has a one year low of $9.53 and a one year high of $17.08. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of 41.28 and a beta of 1.88.

Wall Street Analysts Forecast Growth

Separately, Barclays decreased their price target on shares of Sotera Health from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, April 10th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Sotera Health presently has an average rating of “Moderate Buy” and a consensus price target of $15.20.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.